CASE 


 I've been given these three cases data here 


https://alekyatummala.blogspot.com/2020/09/45-yr-female-with-anasarca.html?m

 This may develop my competency 

a) reading and comprehending clinical data related to the case including history, clinical findings, investigation

b) come up with a diagnosis such as

  • 1) Anatomical location of the root cause
  • 2) Physiological functional disability
  • 3) Biochemical abnormalities that could be a root cause at a molecular lev
  • 4) Pathology that could reflect the root cause at a cellular lev

c) a treatment plan for each of these patients of paraparesis that can have a pharmacological and non pharmacological componency

d) learning the scientific basis of diagnostic and therapeutic approach in terms of past collective experiences and experiments (aka evidence based medicin

The first step to developing these competencies after reading and comprehending each patient data will be :

a) create a problem list for each patient in order of the patient's perceived priori

b) Discuss the root causes for the problem as described above in terms of anatomy, biochemistry and pathology, microbiology

c) discuss possible solutions to tackle these root causes from upstream (soil from which the roots begin) or downstream (to treating the stem and branches aka palliation) in terms of pharmacological (medicinal) and non pharmacological (such as prosthetics, implants) both in historical terms (past dominant treatments for the same cause and it's current evolution) as well as recent advances ( ongoing trials and innovative approaches even at a hypothetical stage


1) What is your complete anatomic and etiologic diagnosis from the data available in the patient's online record linked above? (ignore the provisional diagnosis on admission mentioned in the case report)

Ans-  Anatomic diagnosis: acute kidney injury at glomerulus, mesangial thickening could be the pathoanatomic change with nodular sclerosis AKA kimmelstein Winston lesion

Etiologic diagnosis: diabetic nephropathy


2) What are the reasons for her Azotemia?

Ans- reduced GFR results in reduced excretion of nitrogenous wastes leading to azotemia

Anemia

Erythropoietin deficiency

Hypoalbuminemia

Increased glomerular capillary permeability due 

Acidosis

reduction in GFR leads to reduced H+, and other organic acids excretion leading to acidosis. metabolic acidosis increased anion gap


3) What was the rationale for her treatment plan detailed day wise in the record?

Day1

HCO3 was given to treat acidosis - target HCO3 22meq

potassium was given to counteract hypookalemia


 Day2

insulin was given to correct hyperglycemia

pantoprazole was given to prevent curling ulcer

Vitamin B9 or Folic Acid, iron was given to reat anaem

furocemide was given to reduce fluid overload (evidenced by pulmonary edem


 Day3

furcemide - reduce fluid overload 

spirinolactone - reduce potassium loss from furosemide

Vitamin B9 or Folic Acid, iron was given to reat anaem

nicardipine -  to achieve target BP of 130/

erythropoietin to treat underlying cause of anemia 

calcium and vitamin d3 - reduce renal osteodystrophy

tab sodium bicarbonate - reduce/prevent metabolic acidos

potassium was given to counteract hypokalemia

renal replacement there

Day4

lactulose to reduce encephalopathy

protien to counteract protien low

ceftrioxone to prevent infection as a risk of renal replacement thera

Particularly mention rationale and  efficacy for some of the drugs administered such as oral and iv bicarbonate? When is iv or oral bicarbonate indicated and why is it contraindicated in certain situations?


   Metabolic acidosis in patients with chronic kidney disease: Oral (off-label): Note: KDIGO guidelines suggest oral replacement when plasma HCO3- concentrations are <22 mEq/L (KDIGO 2013


 Initial: 15.4 to 23.1 mEq/day in divided doses (eg, 650 mg tablet 2 to 3 times daily); titrate to normal serum bicarbonate concentrations (eg, 23 to 29 mEq/L) or up to 5850 mg/day; baking soda may be used as an alternative in patients who cannot take tablets (Chen 2014; KDIGO 2013; Kovesdy 2009; Raphael 2016). Avoid exceeding serum bicarbonate concentrations >32 mEq/L since this has been associated with increased mortality in patients with CKD (Navaneethan 2011

https://www.uptodate.com/contents/sodium-bicarbonate-drug-information?topicRef=127552&source=see_li

https://reference.medscape.com/drug/sodium-bicarbonate-3423


4) What was the indication for dialysing her and what was the crucial factor that led to the decision to dialyze her on the third day of admission?

"Intractable dependent oedema resistant to diuretic

Pulmonary oedema

Severe hypertension

Potassium resistant to dietary control and medical intervention

Uraemic syndrome including anorexia, nausea, lethargy etc. (generally not until eGFR < 10 mL/min/1.73 m2

Chronic acidosis resistant to bicarbonate therapy

Intractable anemia despite erythropoietin and iron

Hyperphosphatemia despite binder

(Reference: davidson 23rd edition table 15.)


Indication in this case -

severe shortness of breath - pulmonary edema

metabolic acidosis and refractory anuria


5) What are the other factors other than diabetes and hypertension that led to her current condition?

Failure of secondary prevention that is failure to seak medical help in eary stage of disea



6) What are the expected outcomes in this patient? Compare the outcomes of similar patients globally and share your summary with reference links.

kaplan - Meier survival rate of diabetic CKD is 37%

5year survival is 4

diabetes, low serum albumin, low socioeconomic status of this patient predict poor prognos

FGF-23 levels is a novel marker for mortali



7) How and when would you evaluate her further for cardio renal HFpEF and what are the mechanisms of HFpEF in diabetic renal failure patients


"The complications of CKD result in increased cardiac workload due to hypertension, volume overload, and anemia. Patients with CKD may also have accelerated rates of atherosclerosis and vascular calcification resulting in vessel stiffness


these factors contribute to development left ventricular hypertrophy and left ventricular failu


(Reference: CMDT 2020, topic on chronic kidney diseases)


Frequency of echocardiograph

at time of starting od renal replacement therapy


after 1 month of starting renal replacement therapy


after 3 months of starting or renal replacement therapy


then annually after starting of renal replacement thera


any time if patient's symptoms change


 reference: https://pubmed.ncbi.nlm.nih.gov/1580650


8) What are the efficacies over placebo for the available therapeutic options being provided to her for her anemia


"There was an improvement in haemoglobin (MD 1.90 gm/L, 95% CI -2.34 to -1.47) and haematocrit (MD 9.85%, 95% CI 8.35 to 11.34) with treatment and a decrease in the number of patients requiring blood transfusions (RR 0.32, 95% CI 0.12 to 0.83)


ref: https://pubmed.ncbi.nlm.nih.gov/2679013


9) What is the utility of tools like the CKD-AQ that assess the frequency, severity, and impact on daily activities of symptoms of anemia of CKD? Is Telugu among the 68 languages in which it is translated


There are many studies which prove questionares efficatious and lead to early recognition of symptoms and prompt treatmen


https://doi.org/10.1016/j.jval.2018.09.23


10) What is the contribution of protein energy malnutrition to her severe hypoalbuminemia? What is the utility of tools such as SGA subjective global assessment in the evaluation of malnutrition in CRF patient


"subjective global assessment can be used effectively by providers from different disciplines, such as nursing, dietitians, and physicians; and in some studies has beenfound to be reproducible, valid, and reliable



reference:

https://www.researchgate.net/publication/8232450_Subjective_Global_Assessment_in_chronic_kidney_disease_a_revie



2) A similar patient data as above with diabetes and renal failure with metabolic acidosis and hypoalbuminemia logged by intern Dr Bhavya here

https://bhavyayammanuru.blogspot.com/2020/09/aki-secondary-to-uti.html?m


Please comment on the differences in the diagnosis, therapy and outcomes in both these two patient


case 1: chronic kidney disea


The aims of management in CKD are to


• monitor renal functio


• prevent or slow further renal damag


• limit complications of renal failur


• treat risk factors for cardiovascular diseas


• prepare for RRT, if appropria


Case 2: acute kidney inju


•fluid stat


If hypovolaemic: optimise systemic haemodynamic sta


If fluid-overloaded, prescribe diuret


•correct hyperkalaemia if K+ > 6.5 mmol


•correct acidosis if H+ is > 100 nmol/L (pH < 7.0) - administer bicarbona


• Discontinue potentially nephrotoxic drugs and reduce doses of therapeutic dru


• nutritional suppor


•proton pump inhibitors to reduce curling ulce


• Screen for infections and tre


• In case of urinary tract obstruction, drain lower or upper urinary tract as necessa


Would you agree with the provisional diagnosis shared for this  58 M in the online case report linked abov


yes, there was no symptoms suggesting of pre renal AKI like Volume depletion (vomiting, diarrhoea, burns, haemorrhage) Drugs (diuretics, ACE inhibitors, ARBs, NSAIDs, iodinated contrast) Liver disea


and symptoms like  "Decreased urinary stream since 3days  not passing urine since 1 day Pain abdomen since 1day." suggest a post renal A


What are the findings in the ultrasound of both kidneys? How do you explain those findings? Would it explain the etiology for his renal failure?


It is normal in si


corticomedullary differentiation norm


pelvi calyceal saperation norm


in pre renal aki there is less perfusion to kidney and kidney is structurally norma


doppler imaging would help in confirming less perfusi


loss of cortico medullary differintation is seen in CKD which helps in rulling out the conditi


pelvi calyceal sustem is dilated in post renal AKI which helps in rulling out the condition I've been given these three cases data her


https://alekyatummala.blogspot.com/2020/09/45-yr-female-with-anasarca.html?m



 This may develop my competency 



a) reading and comprehending clinical data related to the case including history, clinical findings, investigati


b) come up with a diagnosis such a


1) Anatomical location of the root cau


2) Physiological functional disabili


3) Biochemical abnormalities that could be a root cause at a molecular lev


4) Pathology that could reflect the root cause at a cellular lev


c) a treatment plan for each of these patients of paraparesis that can have a pharmacological and non pharmacological componen


A


d) learning the scientific basis of diagnostic and therapeutic approach in terms of past collective experiences and experiments (aka evidence based medicin


The first step to developing these competencies after reading and comprehending each patient data will be 


a) create a problem list for each patient in order of the patient's perceived priori


b) Discuss the root causes for the problem as described above in terms of anatomy, biochemistry and pathology, microbiolo


a


c) discuss possible solutions to tackle these root causes from upstream (soil from which the roots begin) or downstream (to treating the stem and branches aka palliation) in terms of pharmacological (medicinal) and non pharmacological (such as prosthetics, implants) both in historical terms (past dominant treatments for the same cause and it's current evolution) as well as recent advances ( ongoing trials and innovative approaches even at a hypothetical stage



1) What is your complete anatomic and etiologic diagnosis from the data available in the patient's online record linked above? (ignore the provisional diagnosis on admission mentioned in the case repo




Anatomic diagnosis: acute kidney injury at glomerulus, mesangial thickning could be the pathoanatomic change with nodular sclerosis AKA kimmelstein Winston lesio


Etiologic diagnosis: diabetic nephropat



2) What are the reasons for her


Azotemi


reduced GFR results in reduced excretion of nitrogenous wastes leading to azothem


Anemi


Erythropoietin defecien


Hypoalbuminemi


Increased glomerular capillary permeability due 


Acidosi


reduction in GFR leads to reduced H+, and other organic acids excretion leading to acidosis. metabolic acidosis increased anion g



3) What was the rationale for her treatment plan detailed day wise in the record?


Day


HCO3 was given to treat acidosis - target HCO3 22meq


potassium was given to counteract hypookalemi


 Day


insulin was given to correct hyperglycem


pantoprazole was given to prevent curling ulc


Vitamin B9 or Folic Acid, iron was given to reat anaem


furocemide was given to reuce fluid overload (evidenced by pulmonary edem


 Day


furcemide - reduce fluid overlo


spirinolactone - reduce potasium loss from furocemi


Vitamin B9 or Folic Acid, iron was given to reat anaem


nicardipine -  to achieve target BP of 130/


eruthropoietin to treart underlying cause of anaem


calcium and vitamin d3 - reuce renal osteodystrop


tab sodium bicarbonate - reduce/prevent metabolic acidos


potassium was given to counteract hypookalemi



renal replacement ther


Day


lactulose to reduce encephalopat


protien to counteract protien lo


ceftrioxone to prevent infection as a risk of renal replacement thera



Particularly mention rationale and  efficacy for some of the drugs administered such as oral and iv bicarbonate? When is iv or oral bicarbonate indicated and why is it contraindicated in certain situations?


   


    Metabolic acidosis in patients with chronic kidney disease: Oral (off-label): Note: KDIGO guidelines suggest oral replacement when plasma HCO3- concentrations are <22 mEq/L (KDIGO 2013


    Initial: 15.4 to 23.1 mEq/day in divided doses (eg, 650 mg tablet 2 to 3 times daily); titrate to normal serum bicarbonate concentrations (eg, 23 to 29 mEq/L) or up to 5850 mg/day; baking soda may be used as an alternative in patients who cannot take tablets (Chen 2014; KDIGO 2013; Kovesdy 2009; Raphael 2016). Avoid exceeding serum bicarbonate concentrations >32 mEq/L since this has been associated with increased mortality in patients with CKD (Navaneethan 2011


https://www.uptodate.com/contents/sodium-bicarbonate-drug-information?topicRef=127552&source=see_li


https://reference.medscape.com/drug/sodium-bicarbonate-3423



4) What was the indication for dialysing her and what was the crucial factor that led to the decision to dialyze her on the third day of admission?


"Intractable dependent oedema resistant to diureti


Pulmonary oedem


Severe hypertensi


Potassium resistant to dietary control and medical interventio


Uraemic syndrome including anorexia, nausea, lethargy etc. (generally not until eGFR < 10 mL/min/1.73 m2


Chronic acidosis resistant to bicarbonate therap


Intractable anaemia despite erythropoietin and iro


Hyperphosphataemia despite binder


Reference: davidson 23rd edition table 15.



Indication in this case 


severe shortness of breath - pulmonary ede


metabolic acidosis and refractory anur



5) What are the other factors other than diabetes and hypertension that led to her current condition?


Failure of secondary prevention that is failure to seak medical help in eary stage of disea



6) What are the expected outcomes in this patient? Compare the outcomes of similar patients globally and share your summary with reference links.


kaplan - Meier survival rate of diabetic CKD is 37%


5year survival is 4


diabetes, low serum albumin, low socioeconomic status of this patient predict poor prognos


FGF-23 levels is a novel marker for mortali



7) How and when would you evaluate her further for cardio renal HFpEF and what are the mechanisms of HFpEF in diabetic renal failure patients


"The complications of CKD result in increased cardiac workload due to hypertension, volume overload, and anemia. Patients with CKD may also have accelerated rates of atherosclerosis and vascular calcification resulting in vessel stiffness


these factors contribute to development left ventricular hypertrophy and left ventricular failu


Reference: CMDT 2020, topic on chronic kidney diseas



Frequency of echocardiograph


at time of starting od renal replacement therap


after 1 month of starting renal replacement thera


after 3 months of starting or renal replacement thera


then annually after starting of renal replacement thera


any time if patient's symptoms change


 reference: https://pubmed.ncbi.nlm.nih.gov/1580650


8) What are the efficacies over placebo for the available therapeutic options being provided to her for her anemia


"There was an improvement in haemoglobin (MD 1.90 gm/L, 95% CI -2.34 to -1.47) and haematocrit (MD 9.85%, 95% CI 8.35 to 11.34) with treatment and a decrease in the number of patients requiring blood transfusions (RR 0.32, 95% CI 0.12 to 0.83)


ref: https://pubmed.ncbi.nlm.nih.gov/2679013


9) What is the utility of tools like the CKD-AQ that assess the frequency, severity, and impact on daily activities of symptoms of anemia of CKD? Is Telugu among the 68 languages in which it is translated


There are many studies which prove questionares efficatious and lead to early recognition of symptoms and prompt treatmen


https://doi.org/10.1016/j.jval.2018.09.23


10) What is the contribution of protein energy malnutrition to her severe hypoalbuminemia? What is the utility of tools such as SGA subjective global assessment in the evaluation of malnutrition in CRF patient


"subjective global assessment can be used effectively by providers from different disciplines, such as nursing, dietitians, and physicians; and in some studies has beenfound to be reproducible, valid, and reliable



reference:


https://www.researchgate.net/publication/8232450_Subjective_Global_Assessment_in_chronic_kidney_disease_a_revie



2) A similar patient data as above with diabetes and renal failure with metabolic acidosis and hypoalbuminemia logged by intern Dr Bhavya here


https://bhavyayammanuru.blogspot.com/2020/09/aki-secondary-to-uti.html?m



Please comment on the differences in the diagnosis, therapy and outcomes in both these two patient


case 1: chronic kidney disea


The aims of management in CKD are to


• monitor renal functio


• prevent or slow further renal damag


• limit complications of renal failur


• treat risk factors for cardiovascular diseas


• prepare for RRT, if appropria


Case 2: acute kidney inju


•fluid stat


If hypovolaemic: optimise systemic haemodynamic sta


If fluid-overloaded, prescribe diuret


•correct hyperkalaemia if K+ > 6.5 mmol


•correct acidosis if H+ is > 100 nmol/L (pH < 7.0) - administer bicarbona


• Discontinue potentially nephrotoxic drugs and reduce doses of therapeutic dru


• nutritional suppor


•proton pump inhibitors to reduce curling ulce


• Screen for infections and tre


• In case of urinary tract obstruction, drain lower or upper urinary tract as necessa


Would you agree with the provisional diagnosis shared for this  58 M in the online case report linked abov


yes, there was no symptoms suggesting of pre renal AKI like Volume depletion (vomiting, diarrhoea, burns, haemorrhage) Drugs (diuretics, ACE inhibitors, ARBs, NSAIDs, iodinated contrast) Liver disea


and symptoms like  "Decreased urinary stream since 3days  not passing urine since 1 day Pain abdomen since 1day." suggest a post renal A


What are the findings in the ultrasound of both kidneys? How do you explain those findings? Would it explain the etiology for his renal failure?


It is normal in si


corticomedullary differentiation norm


pelvi calyceal saperation norm


in pre renal aki there is less perfusion to kidney and kidney is structurally norma


doppler imaging would help in confirming less perfusi


loss of cortico medullary differintation is seen in CKD which helps in rulling out the conditi


pelvi calyceal sustem is dilated in post renal AKI which helps in rulling out the condition ononl alalze  KIsee?ryatrst gste/Lictuusrytee e e n : ses. =1 

 w  

 ."s?21t.? 5/."? 2/  pypypyy y

 e.re."?

 tyis0%,  

 se 

 iama 

 35s"n y ) n ona cs 

 05nk).).   

 pysshy 5apya ishyia80iadead 3a)iaeria 2a /l 1 

 aps toa cya iaa :

 hyns

 rt)).ndgytytoe)ndt.eleltyses:onsin =1e ononl alalze  KIsee?ryatrst gste/Lictuusrytee e e n : ses. =1 

 w  

 ."s?21t.? 5/."? 2/  pypypyy y

 e.re."?

 tyis0%,  

 se 

 iama 

 35s"n y ) n ona cs 

 05nk).).   

 pysshy 5apya ishyia80iadead 3a)iaeria 2a /l 1 

 aps toa cya iaa :

 hyns

 rt)).ndgytytoe)ndt.eleltyses:onsin =1kidney is structurally normal 


doppler imaging would help in confirming less perfusion


loss of cortico medullary differintation is seen in CKD which helps in rulling out the condition


pelvi calyceal sustem is dilated in post renal AKI which helps in rulling out the condition 

Comments

Popular posts from this blog

36M with diabetic neuropathy

NEPHROTIC SYNDROME WITH TYPE -I DM, HYPERTENSION,RIGHT PLEURAL EFFUSION

65 yr old male pt AKI ON CKD 2° TO HTN